

I заседание МНК онкологии



03.10.2019

Структура доклада

1. Организационные вопросы
1. Поиск достоверной информации и принципы работы с ней

МНК онкологии

- заседания кружка, обсуждение методов лечения в онкологии, новостей науки, разбор клинических случаев, совместные заседания;
- научно-практические конференции;
- Олимпиада по онкологии для студентов;
- работа над научными статьями, публикации в журналах и сборниках.

Руководитель МНК

КИТ Олег Иванович



Заведующий кафедрой онкологии с курсом онкологии ФПК и ППС РостГМУ. Директор Ростовского научно-исследовательского онкологического института

Доктор медицинских наук, профессор

Член-корреспондент РАН, заслуженный врач Российской Федерации, главный внештатный онколог Южного федерального округа.

Куратор МНК

НИКОЛАЕВА Надежда Владимировна



Ассистент кафедры онкологии РостГМУ

Доктор медицинских наук

Врач-гематолог отделения онкогематологии
ФГБУ «РНИОИ» Минздрава России.

Староста МНК

СОКОЛИКОВА Виктория

студентка 5 курса ЛПФ

Телефон: 89185467758

Личная почта: viktoria.sokolikova@gmail.com

Почта МНК: OncoRGMU@gmail.com

МНК в социальных сетях

ВКонтакте:

“МНК кафедры онкологии РостГМУ”

https://vk.com/oncology_rostgmu

В группе “МНО РостГМУ”

https://vk.com/mno_rostgmu



МНО

Хочу написать научную работу, что делать?

1. Подумайте над темой
2. Займитесь поиском актуальной проблемы
3. Ознакомьтесь с профессиональными интересами преподавателей и врачей кафедры и клиники
4. Сформулируйте свои пожелания и планы
5. Сообщите старосте МНК о старте работы

Я учусь на первом курсе.

Есть ли смысл посещать заседания?

Конечно!

1. Опыт публичных выступлений
2. Опыт в работе над статьями
3. Профориентация

Хочу подготовить доклад для кружка!

1. Сообщить желаемую тему старосте МНК не позднее, чем за ДВЕ НЕДЕЛИ до заседания
2. Работа должна проводиться под контролем Вашего преподавателя или научного руководителя
3. Готовую презентацию и конспект устного доклада прислать старосте НА ПОЧТУ, не позднее, чем за ПЯТЬ ДНЕЙ до выступления

Поиск достоверной информации и принципы работы с ней

Рубрикация
Указатель А—Я
Избранные статьи
Случайная статья
Текущие события

Участие

Сообщить об ошибке
Сообщество
Форум
Свежие правки
Новые страницы
Справка
Пожертвовать

Инструменты

Ссылки сюда
Связанные правки
Служебные страницы
Постоянная ссылка
Сведения о странице
Цитировать страницу

Печать/экспорт

Создать книгу
Скачать как PDF
Версия для печати

В других проектах

Викисклад
Элемент Викиданных



В этой статье не хватает ссылок на источники информации.

Информация должна быть проверяема, иначе она может быть поставлена под сомнение и удалена.

Вы можете отредактировать эту статью, добавив ссылки на авторитетные источники.

Эта отметка установлена 20 марта 2017 года.

Нефробласто́ма (*опухоль Вильмса*) — высокозлокачественная эмбриональная *опухоль*, происходящая из развивающихся тканей почек.

Заболевание является наиболее частым злокачественным новообразованием мочеполового тракта у детей. Наиболее часто встречается в возрасте до 5 лет с одинаковой частотой у мальчиков и девочек. Установлена связь между возрастом матери и вероятностью родить ребёнка с нефробластомой. Опухоль Вильмса часто сочетается и с врождёнными аномалиями развития.

Своё название опухоль Вильмса получила в честь немецкого хирурга Макса Вильмса (1867—1918), предложившего в 1899 г. в своей монографии обзор литературы по опухолям почек у детей и обосновавшего гистогенез опухоли.

Содержание [скрыть]

- Гистологическое строение
- Клинические проявления
- Диагностика
- Классификация
 - Стадии
- Лечение
- См. также

Нефробластома

| | |
|--------------------|------------------------|
| МКБ-10 | C64 ↗ |
| МКБ-9 | 189.0 ↗ |
| МКБ-O | 8960/3 ↗ |
| OMIM | 194070 ↗ |
| DiseasesDB | 8896 ↗ |
| MedlinePlus | 001575 ↗ |
| MeSH | D009396 ↗ |

Гистологическое строение [править | править код]



Этот раздел не завершён.

Вы можете помочь проекту, исправив и дополнив его.

Меняем язык на английский

На других языках 

العربية
Deutsch
English
Español
Suomi
Français
Bahasa Indonesia
Português
中文

★ Ещё 18

 Править ссылки

Гистологическое строение [\[править \]](#) [\[править код \]](#)



Этот раздел не завершён.

Вы можете помочь проекту, [исправив](#) и [дополнив](#) его.

Клинические проявления [\[править \]](#) [\[править код \]](#)

Клинически опухоль обычно обнаруживается родителями или педиатром во время осмотра внешне здорового ребёнка. Представляет собой плотное безболезненное образование в брюшной полости, часто имеющее гладкую или неровную поверхность. Иногда единственным симптомом заболевания является появление крови в моче **макроематурия**, которое является следствием прорастания опухоли в чашечную систему почки. Кроме того, могут быть и неспецифичные симптомы, например **лихорадка**, повышение артериального давления, желудочно-кишечные расстройства или просто общее недомогание.

В редких случаях первым проявлением опухоли Вильмса является болевой синдром, который наиболее



WIKIPEDIA
The Free Encyclopedia

- Main page
- Contents
- Featured content
- Current events
- Random article
- Donate to Wikipedia
- Wikipedia store

Interaction

- Help
- About Wikipedia
- Community portal
- Recent changes
- Contact page

Tools

- What links here
- Related changes
- Upload file
- Special pages
- Permanent link
- Page information
- Wikidata item

Not logged in - [Talk](#) [Contributions](#) [Create account](#) [Log in](#)

Article [Talk](#)

[Read](#) [Edit](#) [View history](#)

Wilms' tumor

From Wikipedia, the free encyclopedia

Wilms' tumor, also known as **nephroblastoma**, is a cancer of the kidneys that typically occurs in children, rarely in adults.^[1] It is named after Max Wilms, the German surgeon (1867–1918) who first described it.^[2]

Approximately 650 cases are diagnosed in the U.S. annually.^[3] The majority of cases occur in children with no associated genetic syndromes; however, a minority of children with Wilms' tumor have a congenital abnormality.^[3] It is highly responsive to treatment, with about 9/10 children being cured.^[3]

Contents [hide]

- Signs and symptoms
- Pathogenesis
 - Molecular biology and related conditions
- Diagnosis
 - Staging
- Treatment/prognosis
- Epidemiology
- History
- Notable Cases
- See also
- References
- External links

Wilms' tumor

Other names Wilms' tumor



Cut section showing two halves of a nephroblastoma specimen. Note the prominent septa subdividing the sectioned surface and the protrusion of tumor into the renal pelvis, resembling botryoid rhabdomyosarcoma.

Pronunciation ˈwɪlmz

Specialty Oncology, urology, nephrology

Tumor 1 (WT1) or Wilms Tumor 2 (WT2) genes, and the tumor presents with a group of other signs and symptoms.^[3] Non-syndromic Wilms' tumor is not associated with other symptoms or pathologies.^[3] Many, but not all, cases of Wilms' tumor develop from nephrogenic rests, which are fragments of tissue in or around the kidney that develop before birth and become cancerous after birth. In particular, cases of bilateral Wilms' tumor, as well as cases of Wilms' tumor derived from certain genetic syndromes such as Denys-Drash syndrome, are strongly associated with nephrogenic rests.^[3] Most nephroblastomas are on one side of the body only and are found on both sides in less than 5% of cases, although people with Denys-Drash syndrome mostly have bilateral or multiple tumors.^[3] They tend to be encapsulated and vascularized tumors that do not cross the midline of the abdomen. In cases of metastasis it is usually to the lung. A rupture of Wilms' tumor puts the patient at risk of bleeding and peritoneal dissemination of the tumor. In such cases, surgical intervention by a surgeon who is experienced in the removal of such a fragile tumor is imperative.

Pathologically, a triphasic nephroblastoma comprises three elements:

- blastema
- mesenchyme (stroma)
- epithelium

Wilms' tumor is a malignant tumor containing *metanephric blastema*, stromal and epithelial derivatives. Characteristic is the presence of abortive tubules and glomeruli surrounded by a spindled cell stroma. The stroma may include striated muscle, cartilage, bone, fat tissue, and fibrous tissue. Dysfunction is caused when the tumor compresses the normal kidney parenchyma.

The mesenchymal component may include cells showing rhabdomyoid differentiation or malignancy (rhabdomyosarcomatous Wilms).

Wilms' tumors may be separated into 2 prognostic groups based on pathologic characteristics:


- Favorable - Contains well developed components mentioned above
- Anaplastic - Contains diffuse anaplasia (poorly developed cells)

Molecular biology and related conditions [edit]


Mutations of the WT1 gene on chromosome 11p13 are observed in approximately 20% of Wilms' tumors.^{[7][8]} At least half of the Wilms' tumors with mutations in WT1 also carry mutations in CTNNB1, the gene encoding the proto-oncogene beta-catenin.^[9]

Most cases do not have mutations in any of these genes.^[10]

| Syndrome Name | Associated Genetic Variant | Risk for Wilms tumor | Description of Syndrome |
|---|---|----------------------|--|
| WAGR syndrome (Wilms tumor, aniridia, genital anomalies, retardation) | Gene deletion that includes both <i>WT1</i> and <i>PAX6</i> | 45-60% | Characterized by Wilms tumor, aniridia (absence of iris), hemihypertrophy (one side of body larger than the other), genitourinary abnormalities, ambiguous genitalia, intellectual disability. ^[11] |
| Denys-Drash syndrome (DDS) | <i>WT1</i> (exon 8 and 9) | 74% | Characterized by kidney diseases since birth leading to early-onset kidney failure, ambiguous genitalia (intersex disorders). ^[11] |
| Beckwith-Wiedemann Syndrome | Abnormal regulation of chromosome 11p15.5 | 7% | Characterized by macrosomia (large birth size), macroglossia (large tongue), hemihypertrophy (one side of the body is larger), other tumors in body, omphalocele (open abdominal wall) and visceromegaly (enlargement of organs inside abdomen). ^[11] |



Micrograph showing the characteristic triphasic pattern consisting of tubules, solid sheets of small round cells, and stroma. H&E stain.



High magnification micrograph showing the epithelial component (tubules). H&E stain.

Diagnosis [edit]

References/ Источники, использованные материалы

References [edit]

1. [^] EBSCO database verified by URAC; accessed from Mount Sinai Hospital, New York
2. [^] WhoNamedIt.com: Max Wilms
3. ^{^ a b c} "Wilms Tumor and Other Childhood Kidney Tumors Treatment". *National Cancer Institute*. Retrieved 2018-11-12.
4. [^] Williams V, Munikoty V, Trehan A (July 2018). "Varicocele with an Abdominal Mass". *The Journal of Pediatrics*. **198**: 317–317.e1. doi:10.1016/j.jpeds.2018.02.023. PMID 29580678.
5. ^{^ a b c} PDQ Pediatric Treatment Editorial Board (2002). "Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ): Health Professional Version". *PDQ Cancer Information Summaries*, National Cancer Institute (US). PMID 26389282, retrieved 2018-11-26
6. [^] Guaragna MS, Soardi FC, Assumpção JG, Zambaldi L, Cardinalli IA, Nunes JA, de Mello MP, Brandalise SR, Aguiar S (August 2010). "The novel WT1 gene mutation p.H377N associated to Denys-Drash syndrome". *Journal of Pediatric Hematology/Oncology*. **32** (6): 488–8. doi:10.1097/MPH.0b013e3181e5e20d. PMID 20562648.
7. [^] Call KM, Glaser T, Ito CY, Buckler AJ, Pelletier J, Haber DA, Rose EA, Krav A, Yeager H, Lewis WH (February 1990). "Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus". *Cell*. **60** (3): 509–20. doi:10.1016/0092-8674(90)90801-A. PMID 2154335.
8. [^] Huff V (October 1998). "Wilms tumor genetics". *American Journal of Medical Genetics*. **79** (4): 260–7. doi:10.1002/(SICI)1096-8628(19981002)79:4<260::AID-AJMG6>3.0.CO;2-Q. PMID 9781905.
9. [^] Maiti S, Alam R, Amos CI, Huff V (November 2000). "Frequent association of beta-catenin and WT1 mutations in Wilms tumors". *Cancer Research*. **60** (22): 6288–92. PMID 11103785.
10. [^] Ruteshouser EC, Robinson SM, Huff V (June 2008). "Wilms tumor genetics: mutations in WT1, WTX, and CTNNB1 account for only about one-third of tumors". *Genes, Chromosomes & Cancer*. **47** (6): 461–70. doi:10.1002/gcc.20553. PMC 4332772. PMID 18311776.
11. ^{^ a b c} Dome JS, Graf N, Geller JI, Fernandez CV, Mullen EA, Spreafico F, Van den Heuvel-Eibrink M, Pritchard-Jones K (September 2015). "Advances in Wilms Tumor Treatment and Biology: Progress Through International Collaboration". *Journal of Clinical Oncology*. **33** (27): 2999–3007. doi:10.1200/JCO.2015.62.1888. PMC 4567702. PMID 26304882.
12. ^{^ a b} PDQ Pediatric Treatment Editorial Board (2002). *Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ): Health Professional Version*. *PDQ Cancer Information Summaries*. National Cancer Institute (US). PMID 26389282. Retrieved 2018-11-12.
13. ^{^ a b} "Presentation, diagnosis, and staging of Wilms tumor".
14. ^{^ a b} Szycho E, Apps J, Pritchard-Jones K (January 2014). "Wilms' tumor: biology, diagnosis and treatment". *Translational Pediatrics*. **3** (1): 12–24. doi:10.3978/j.issn.2224-4336.2014.01.09. PMC 4728859. PMID 26835318.
15. [^] "How is Wilms tumor staged?". *www.cancer.org*. Retrieved 2015-11-15.
16. [^] "Wilms Tumor - Childhood - Stages". *Cancer.Net*. Retrieved 2015-11-15.
17. [^] "Treatment by type and stage of Wilms tumor". *www.cancer.org*. Retrieved 2015-11-13.
18. [^] Stewénius Y, Jin Y, Øra I, de Kraker J, Bras J, Frigyesi A, Alumets J, Sandstedt B, Meeker AK, Gisselsson D (November 2007). "Defective chromosome segregation and telomere dysfunction in aggressive Wilms' tumors". *Clinical Cancer Research*. **13** (22 Pt 1): 6593–602. doi:10.1158/1078-0432.CCR-07-1081. PMID 18006759.
19. [^] Tournade MF, Com-Nougou C, de Kraker J, Ludwig R, Rey A, Burgers JM, Sandstedt B, Godzinski J, Carli M, Potter R, Zucker JM (January 2001). "Optimal duration of preoperative therapy in unilateral and nonmetastatic Wilms' tumor in children older than 6 months: results of the Ninth International Society of Pediatric Oncology Wilms' Tumor Trial and Study". *Journal of Clinical Oncology*. **19** (2): 488–500. doi:10.1200/JCO.2001.19.2.488. PMID 11208843.
20. [^] Messahel B, Williams R, Ridolfi A, A'hern R, Warren W, Tinworth L, Hobson R, Al-Saadi R, Whyman G, Brundler MA, Kelsey A, Sebire N, Jones C, Vujanec G, Pritchard-Jones K (March 2009). "Allele loss at 16q defines poorer prognosis Wilms tumor irrespective of treatment approach in the UKW1-3 clinical trials: a Children's Cancer and Leukaemia Group (CCLG) Study". *European Journal of Cancer*. **45** (5): 819–26. doi:10.1016/j.ejca.2009.01.005. PMID 19231157.
21. [^] Grundy PE, Breslow NE, Li S, Perlman E, Beckwith JB, Ritchey ML, Shamberger RC, Haase GM, D'Angio GJ, Donaldson M, Coppes MJ, Malogolowkin M, Shearer P, Thomas PR, Macklis R, Tomlinson G, Huff V, Green DM (October 2005). "Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a
22. ^{^ a b c d e f g h i j} Unless otherwise specified in boxes, then reference is: Treatment of Wilms Tumor at National Cancer Institute. Last Modified: 03/29/2012
23. [^] Spreafico F, Pritchard Jones K, Malogolowkin MH, Bergeron C, Hale J, de Kraker J, Dallorso S, Acha T, de Camargo S, Dome JS, Graf N (December 2009). "Treatment of relapsed Wilms tumors: lessons learned". *Expert Review of Anticancer Therapy*. **9** (12): 1807–15. doi:10.1588/era.09.159. PMID 19954292.
24. [^] Sonn G, Shortliffe LM (October 2008). "Management of Wilms tumor: current standard of care". *Nature Clinical Practice. Urology*. **5** (10): 551–60. doi:10.1038/ncpuro1218. PMID 18836464.
25. ^{^ a b} Kalish NJ, Doros L, Helman LJ, Hennekam RC, Kuiper RP, Maas SM, Maher ER, Nichols KE, Plon SE, Porter CC, Rednam S, Schultz KA, Stages LJ, Tomlinson GE, Zellek K, Druley TE (July 2017). "Surveillance Recommendations for Children with Overgrowth Syndromes and Predisposition to Wilms Tumors and Hepatoblastoma". *Clinical Cancer Research*. **23** (13): e115–e122. doi:10.1158/1078-0432.CCR-17-0710. PMC 5538793. PMID 28674120.
26. ^{^ a b} Breslow N, Olshan A, Beckwith JB, Green DM (1993). "Epidemiology of Wilms tumor". *Medical and Pediatric Oncology*. **21** (3): 172–81. doi:10.1002/mpo.2950210305. PMID 7880412.
27. [^] Breslow NE, Beckwith JB, Perlman EJ, Reeve AE (September 2006). "Age distributions, birth weights, nephrogenic rests, and heterogeneity in the pathogenesis of Wilms tumor". *Pediatric Blood & Cancer*. **47** (3): 260–7. doi:10.1002/pbc.20891. PMC 1543866. PMID 16700047.
28. [^] Pritchard-Jones K, Fleming S, Davidson D, Bickmore W, Porteous D, Gosden C, Bard J, Buckler A, Pelletier J, Housman D (July 1990). "The candidate Wilms' tumour gene is involved in genitourinary development". *Nature*. **346** (6280): 194–7. Bibcode:1990Natur.346..194P. doi:10.1038/346194a0. PMID 2164159.
29. [^] Nephroblastoma in childhood: current possibilities for an early radiographic diagnosis, Italian Journal of Surgery 1989

PubMed

NCBI PubMed

PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.

<https://www.ncbi.nlm.nih.gov/pubmed/>

Вводим искомый текст в строку поиска

NCBI Resources How To Sign in to NCBI

PubMed.gov US National Library of Medicine National Institutes of Health

PubMed Wilms' tumor Search

Create RSS Create alert Advanced Help

Article types: Clinical Trial, Review, Customize ...

Text availability: Abstract, Free full text, Full text

Publication dates: 5 years, 10 years, Custom range...

Species: Humans, Other Animals

Clear all Show additional filters

Format: Summary Sort by: Most Recent Per page: 20 Send to Filters: Manage Filters

Search results

Items: 1 to 20 of 12540 << First < Prev Page 1 of 627 Next > Last >>


★ Did you mean: [wilms tumor](#) (12656 items)

[miR-140-5p Alleviates The Aggressive Progression Of Wilms' Tumor Through Directly Targeting TGFBR1 Gene \[Retraction\].](#)
1. [No authors listed]
Cancer Manag Res. 2019 Sep 23;11:8605. doi: 10.2147/CMAR.S231533. eCollection 2019.
PMID: 31576166
[Similar articles](#)

[Wilms tumor with extensive cardiac thrombus: a multidisciplinary approach.](#)
2. Viswanathan A, Kumar N, Mathew AK, Narendra Babu M, Subramanian AP, Appaji L.
Asian Cardiovasc Thorac Ann. 2019 Oct 1;218492319881593. doi: 10.1177/0218492319881593. [Epub ahead of print]
No abstract available.
PMID: 31575285
[Similar articles](#)

[\[Clinical and molecular genetic verification of Frasers syndrome, false male hermaphroditism and chronic glomerulonephritis \(the first description in Russia\)\].](#)
3. Novikova EO, Rubtsov PM, Sverdllova PS, Tyul'pakov AN.
Probl Endokrinol (Mosk). 2009 Apr 15;55(2):51-53. doi: 10.14341/probl200955251-53. Russian.
PMID: 31569903
[Similar articles](#)

Results by year



Download CSV

Titles with your search terms

MicroRNA-483-3p Promotes Proliferation, Migration, and Invasion [Pediatr Dev Pathol. 2019]

The prognostic significance of Wilms' tumor gene 1 (WT1) expression at [Ann Hematol. 2019]

Evidence that downregulation of Wilms' tumor 1 (WT1) is involved in corti [Mol Reprod Dev. 2019]

See more...

Find related data

Format: Abstract ▾

Send to ▾

[Cancer Manag Res](#). 2019 Sep 23;11:8605. doi: 10.2147/CMAR.S231533. eCollection 2019.

miR-140-5p Alleviates The Aggressive Progression Of Wilms' Tumor Through Directly Targeting *TGFBR1* Gene [Retraction].

[No authors listed]

Abstract

[This retracts the article [DOI: 10.2147/CMAR.S177508](#)].

© 2019 Dove Medical Press.

Retraction of

miR-140-5p alleviates the aggressive progression of Wilms' tumor through directly targeting *TGFBR1* gene. [Cancer Manag Res. 2019]

PMID: 31576166 PMCID: [PMC6765099](#) DOI: [10.2147/CMAR.S231533](#)



Publication type



Save items

☆ Add to Favorites ▾

Recent Activity

[Turn Off](#) [Clear](#)

miR-140-5p Alleviates The Aggressive Progression Of Wilms' Tumor Through PubMed

Wilms' tumor (12540)

PubMed

[See more...](#)

DOI

Дискретный идентификатор объекта (англ. Digital Object Identifier = Цифровой идентификатор объекта, сокр. DOI) — стандарт обозначения представленной в сети информации об объекте ГОСТ Р ИСО 26324-2015.

DOI: 10.2147/CMAR.S177508

Sci-Hub

<https://sci-hub.se>



The banner features a black crow with a white outline, holding a red key in its beak. The background is a light-colored brick wall. The text 'SCI-HUB' is written in large, bold, red letters. Below it, a red pencil-shaped box contains the text '...устраняя преграды на пути распространения знаний'. A white search bar contains the text 'URL статьи, PMID / DOI или строка для поиска'. To the right of the search bar is a red button with a white key icon and the text 'открыть'. In the top right corner, there is a gold medal icon with a red ribbon and a black box containing the text: 'первый в мире проект, который открыл публичный и массовый доступ к научным первоисточникам'. At the bottom, a black bar contains the text: 'о проекте', 'принципы', 'сообщество', 'поддержать'.

SCI-HUB

...устраняя преграды на пути распространения знаний

URL статьи, PMID / DOI или строка для поиска

открыть

первый в мире проект, который открыл публичный и массовый доступ к научным первоисточникам

сделано Александрой Элбакян

о проекте принципы сообщество поддержать

Вставляем DOI в поисковую строку



SCI-HUB

...устраняя преграды на пути распространения знаний

DOI: 10.2147/CMAR.S177508

сделано Александрой Элбакян



первый в мире проект,
который открыл
публичный и массовый
доступ к научным
первоисточникам



открыть



sci-hub

знания — всем!

↻ перекачать

↓ сохранить

Wang, H., Lou, C., & Ma, N. (2019).

miR-140-5p alleviates the aggressive progression of Wilms' tumor through directly targeting TGFBR1 gene

. *Cancer Management and Research*,
Volume 11, 1641–1651.
doi:10.2147/cmar.s177508

постоянная ссылка на статью:
[sci-hub.se/10.2147/CMAR.S177508](https://www.dovepress.com/10.2147/CMAR.S177508)

Sci-Hub – проект, который борется за
открытый доступ к научным знаниям
поддержать работу →

wang2019.pdf

1 / 11



Cancer Management and Research

Dovepress

open access to scientific and medical research

 Open Access Full Text Article

ORIGINAL RESEARCH

miR-140-5p alleviates the aggressive progression of Wilms' tumor through directly targeting TGFBR1 gene

This article was published in the following Dove Medical Press journal:
Cancer Management and Research

Hailei Wang¹
Chunyan Lou¹
Na Ma²

¹Department of Pediatrics, Huaihe Hospital of Henan University, Kaifeng, Henan, China; ²Department of Neurology, Henan Kaifeng Children's Hospital, Kaifeng, Henan, China

Background and objective: Although many miRNAs are identified to be deregulated and play vital roles in the progression of Wilms' tumor (WT), there are still a large number of miRNAs are waiting for us to explore. The purpose of the present study is to investigate the different expressing profiles of miRNAs in WT tissues and the adjacent normal tissues, and probe the effects and mechanism of a certain miRNA among the different expressing miRNAs.

Methods: miRNA microarray was recruited to assess the differently expressed miRNAs in WT tissues and normal tissues, which was further verified by RT-PCR. Receiver operating characteristic curves were performed to calculate the specificity and sensitivity of miRNAs in the diagnose of WT. CCK-8, flow cytometry, wound healing, transwell chamber and tumor-burdened assays

om: <https://www.dovepress.com/> by 83.171.253.96 on 14-Mar-2019
personal use only.



Кохрановское сообщество

Cochrane is for anyone interested in using high-quality information to make health decisions. Whether you are a doctor or nurse, patient or carer, researcher or funder, Cochrane evidence provides a powerful tool to enhance your healthcare knowledge and decision making.

We do not accept commercial or conflicted funding. This is vital for us to generate authoritative and reliable information, working freely, unconstrained by commercial and financial interests.

<https://www.cochrane.org/ru/evidence>



Trusted evidence.
Informed decisions.
Better health.

Wilms' tumor



Our evidence

About us

Join Cochrane

News and jobs

Cochrane Library



71 search results for "Wilms' tumor"

Current search:

Wilms' tumor ✕

Reset

Filter your results:

This site

Cochrane Evidence

Training

All Cochrane sites

Search here to find [Cochrane Reviews](#)

[More about searches](#) ▼

Health topics

Cancer (52)

Child health (10)

Gastroenterology & hepatology (19)

Gynaecology (2)

Heart & circulation (3)

Kidney disease (2)

Lungs & airways (4)

Neurology (16)

Rheumatology (7)

Sort by... ▼



[Subscribe to this search](#)

COCHRANE EVIDENCE • Published 16 Apr 2008

Antiepileptic drugs for preventing seizures in people with brain tumors

Up to 60% of people with brain tumors may present with seizures, or may have a seizure for the first time after diagnosis or

Google Scholar

Google Scholar — бесплатная поисковая система по полным текстам научных публикаций всех форматов и дисциплин. Проект работает с ноября 2004 года, первоначально в статусе бета-версии. Индекс Google Scholar включает данные из большинства рецензируемых онлайн журналов крупнейших научных издательств Европы и Америки.

scholar.google.com



Mein Profil



Meine Bibliothek

Google Scholar

Wilms' tumor



- wilms tumor **gene**
- wilms tumor **gene wt1**
- wilms tumor **suppressor wt1**
- wilms tumor **treatment**
- wilms tumor **study**
- wilms tumor **patients**
- wilms tumor **protein**
- wilms tumor **in children**
- wilms tumor **review**
- wilms tumor **genetics**



- Beliebige Zeit
- Seit 2019
- Seit 2018
- Seit 2015
- Zeitraum wählen...

- Nach Relevanz sortieren
- Nach Datum sortieren

- Beliebige Sprache
- Seiten auf Deutsch

- Patente einschließen
- Zitate einschließen
- Alert erstellen

Histopathology and prognosis of **Wilms' tumor** *Results from the first national **wilms' tumor** study*

[PDF] wiley.com

JB Beckwith, NF Palmer - *Cancer*, 1978 - Wiley Online Library
 Detailed histological analysis of 427 cases entered on the first national **Wilms' tumor** study revealed that lesions with foci of marked cytological atypism (anaplasia), and those composed predominantly of sarcomatous stroma, were associated with unfavorable ...
 ☆ Zitiert von: 1440 Ähnliche Artikel Alle 5 Versionen

Treatment of **Wilms' tumor**. Results of the third national **Wilms' tumor** study

[PDF] wiley.com

GJ D'angio, N Breslow, JB Beckwith, A Evans... - *Cancer*, 1989 - Wiley Online Library
 Abstract The Third National **Wilms' Tumor** Study sought to reduce treatment for low-risk patients and find better chemotherapy for those at high risk for relapse. Eligible patients (1439) were randomized according to stage (I-IV) and histology (favorable [FH] or ...
 ☆ Zitiert von: 738 Ähnliche Artikel Alle 12 Versionen

Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 **Wilms' tumor** locus

KM Call, T Glaser, CY Ito, AJ Buckler, J Pelletier... - *Cell*, 1990 - Elsevier
 We have isolated a series of genomic and cDNA clones mapping within the boundaries of constitutional and **tumor** deletions that define the **Wilms' tumor** locus on human chromosome 11 (band p13). The transcription unit corresponding to these clones spans approximately 50 ...
 ☆ Zitiert von: 2124 Ähnliche Artikel Alle 9 Versionen

Mutation and cancer: a model for **Wilms' tumor** of the kidney

AG Knudson Jr, LC Strons - *Journal of the National Cancer ...*, 1972 - academic.oup.com
 Statistical analysis of cases of **Wilms' tumor** supports a 2-mutation model previously reported for retinoblastoma. Comparison of data for familial, bilateral, unilateral, and unselected cases reveals that familial and bilateral cases have an early average age of diagnosis with

NCCN

The National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education/

<https://www.nccn.org/>



National Comprehensive Cancer Network®

National Comprehensive Cancer Network

Follow us on:     

Donate to the NCCN Foundation

| | | | | | | | | |
|----------------------------------|--------------------------------|---------------------------------|---|--|---|-----------------------------|--|-----------------------------------|
| NCCN Guidelines® | NCCN Compendia | NCCN Templates® | Educational Events & Programs | Subscriptions & Products | Clinical & Business Resources | NCCN Global | NCCN Oncology Research Program | Patient Resources |
|----------------------------------|--------------------------------|---------------------------------|---|--|---|-----------------------------|--|-----------------------------------|

NCCN Guidelines®

- [About The NCCN Clinical Practice Guidelines in Oncology \(NCCN Guidelines®\)](#)
- [Development and Update of the NCCN Guidelines](#)
- [Recent Updates to NCCN Guidelines®](#)
- [NCCN Guidelines Panels - Meeting Schedule](#)
- [NCCN Categories of Evidence and Consensus](#)
- [NCCN Categories of Preference](#)
- [NCCN Guidelines® Steering Committee](#)
- [Transparency: Process and Recommendations](#)
- [Submission Request to the NCCN Guidelines Panels](#)
- [Submission Request History](#)
- [Permissions Requests](#)

NCCN Guidelines® & Clinical Resources

NCCN Guidelines®

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) are posted with the latest update date and version number.

The NCCN Guidelines are copyrighted by the NCCN. All rights reserved. NCCN Guidelines and illustrations (including algorithms) may not be reproduced in any form for any purpose without the express written permission of the NCCN. [Permissions Requests Section](#).

[Click here to view the NCCN Guidelines Panel Members individual disclosures](#)

- [NCCN Guidelines for Treatment of Cancer by Site](#)
- [NCCN Guidelines for Detection, Prevention, & Risk Reduction](#)
- [NCCN Guidelines for Supportive Care](#)
- [NCCN Guidelines for Specific Populations](#)
- [NCCN Guidelines for Patients](#)

The NCCN guidelines are FREE! Register for a free account, then click on the cancer types below to display a drop down of options. If you are still having an issue, please [contact us](#).

NCCN GUIDELINES FOR TREATMENT OF CANCER BY SITE

Quick Links

- [NCCN Guidelines® - FREE](#)
- [NCCN Compendium®](#)
- [NCCN Biomarkers Compendium®](#)
- [NCCN Imaging AUC™](#)
- [NCCN Radiation Therapy Compendium™](#)
- [NCCN Templates®](#)
- [Educational Events](#)
- [CME/CE Programs](#)
- [NCCN Guidelines for Patients®](#)

Clinical Key

Drive decision-making with a clinical search engine that gives you quick access to better evidence.

<https://www.clinicalkey.com>



Поиск условий, процедур, лекарственных средств и другое

все виды



поиск



Браузер

[Книги](#)

[Журналы](#)

[Монографии на лекарственные средства](#)

[Руководства](#)

[Образование пациентов](#)





ELSEVIER

About Elsevier

Products & Solutions

Services

Shop & Discover

Search 



Search for books, journals or webpages...

Wilms tumor



All Pages Books Journals


2 160 search results found for "Wilms tumor" in all (0.41 seconds)

Translational Immunotherapy of Brain Tumors - 1st Edition

<https://www.elsevier.com/books/translational-immunotherapy-of-brain-tumors/samps...>

Translational Immunotherapy of Brain Tumors gives researchers and practitioners an up-to-date and comprehensive overview of the field. Chapters include adoptive immunothe...

Books



Up to date

UpToDate, electronic clinical resource tool for physicians and patients that provides information on Adult Primary Care and Internal Medicine

<https://www.uptodate.com>

Showing results for **Wilms' tumor**[All](#)[Adult](#)[Pediatric](#)[Patient](#)[Graphics](#)

[Presentation, diagnosis, and staging of Wilms tumor](#)

... patients . **Wilms tumor** is primarily a sporadic disease, and only 1 to 2 percent of individuals with **Wilms tumor** have a relative with the disease . In approximately 10 percent of cases, **Wilms tumor** occurs as ...

[Treatment and prognosis of Wilms tumor](#)

...outcome of **Wilms tumor** will be reviewed here. The epidemiology, presentation, diagnosis, and staging of **Wilms tumor** are discussed separately. Several prognostic factors at the time of initial diagnosis are ...

[Beckwith-Wiedemann syndrome](#)

...percent for tumors. Previously, the risk for **Wilms tumor** in children with loss of maternal methylation at IC2 was only rarely reported. However, **Wilms tumor** has now been reported in several children with ...

[Clinical assessment of the child with suspected cancer](#)

...particular types of cancer varies depending upon the age of the child For example, neuroblastoma and **Wilms tumor** occur most commonly in children between birth and four years of age; leukemia occurs most often ...

[Acquired von Willebrand syndrome](#)

...have initiated testing for aVWS in all patients with suspected **Wilms tumor** at their institution. We test for aVWS in any patient with **Wilms tumor** who has a bleeding history or who requires surgery or other ...

[Renal cystic diseases in children](#)



Learn how UpToDate can help you.

For more information on subscription options, click below on the option that best describes you:

[Medical Professional](#)[Resident, Fellow, or Student](#)[Hospital or Institution](#)[Group Practice](#)

Спасибо за внимание! Удачи!

"Student, you do not study to pass the test. You study to prepare for the day when you are the only thing between a patient and the grave."

-Mark Reid, MD.